ATE78262T1 - Hybrid-interferone. - Google Patents

Hybrid-interferone.

Info

Publication number
ATE78262T1
ATE78262T1 AT86810243T AT86810243T ATE78262T1 AT E78262 T1 ATE78262 T1 AT E78262T1 AT 86810243 T AT86810243 T AT 86810243T AT 86810243 T AT86810243 T AT 86810243T AT E78262 T1 ATE78262 T1 AT E78262T1
Authority
AT
Austria
Prior art keywords
interferons
hybrid interferons
novel hybrid
hybrid
interferon
Prior art date
Application number
AT86810243T
Other languages
English (en)
Inventor
Francois Meyer
Albert Hinnen
Andreas Meister
Markus G Gruetter
Sefik Alkan
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB858514725A external-priority patent/GB8514725D0/en
Priority claimed from GB858514722A external-priority patent/GB8514722D0/en
Priority claimed from GB858514726A external-priority patent/GB8514726D0/en
Priority claimed from GB858514723A external-priority patent/GB8514723D0/en
Priority claimed from GB858514724A external-priority patent/GB8514724D0/en
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Application granted granted Critical
Publication of ATE78262T1 publication Critical patent/ATE78262T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/142—Interferon

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT86810243T 1985-06-11 1986-06-05 Hybrid-interferone. ATE78262T1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB858514725A GB8514725D0 (en) 1985-06-11 1985-06-11 Hybrid polypeptide
GB858514722A GB8514722D0 (en) 1985-06-11 1985-06-11 Hybrid interferon
GB858514726A GB8514726D0 (en) 1985-06-11 1985-06-11 Hybrid polypeptides
GB858514723A GB8514723D0 (en) 1985-06-11 1985-06-11 Hybrid alpha-interferon
GB858514724A GB8514724D0 (en) 1985-06-11 1985-06-11 Hybrid alpha-interferon
EP86810243A EP0205404B1 (de) 1985-06-11 1986-06-05 Hybrid-Interferone

Publications (1)

Publication Number Publication Date
ATE78262T1 true ATE78262T1 (de) 1992-08-15

Family

ID=27516593

Family Applications (1)

Application Number Title Priority Date Filing Date
AT86810243T ATE78262T1 (de) 1985-06-11 1986-06-05 Hybrid-interferone.

Country Status (20)

Country Link
US (2) US4885166A (de)
EP (1) EP0205404B1 (de)
JP (2) JPH0655759B2 (de)
KR (1) KR920002267B1 (de)
AT (1) ATE78262T1 (de)
AU (1) AU598196B2 (de)
CA (1) CA1285507C (de)
CY (1) CY1842A (de)
DE (1) DE3685996T2 (de)
DK (1) DK168794B1 (de)
FI (1) FI90983C (de)
GR (1) GR861497B (de)
HK (1) HK99895A (de)
HU (1) HU203255B (de)
IE (1) IE57865B1 (de)
IL (1) IL79085A (de)
NO (1) NO175602C (de)
NZ (1) NZ216485A (de)
PT (1) PT82736B (de)
SG (1) SG25195G (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5359035A (en) * 1985-12-21 1994-10-25 Hoechst Aktiengesellschaft Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF)
DE3607835A1 (de) * 1986-03-10 1987-09-24 Boehringer Ingelheim Int Hybridinterferone, deren verwendung als arzneimittel und als zwischenprodukte zur herstellung von antikoerpern und deren verwendung sowie verfahren zu ihrer herstellung
GB8803365D0 (en) * 1988-02-13 1988-03-16 Ciba Geigy Ag Antiviral combination
EP0331635A3 (de) * 1988-02-29 1990-02-28 The Board of Regents of the University of Texas System Zubereitungen zur Behandlung von Blasenkrebs.
US5273889A (en) * 1990-08-22 1993-12-28 University Of Saskatchewan Gamma-iterferon-leukotoxin gene fusions and uses thereof
US5594107A (en) * 1990-08-22 1997-01-14 University Of Saskatchewan Chimeric protein comprising an RTX-family cytotoxin and interferon-2 or interferon
ATE167896T1 (de) * 1990-08-29 1998-07-15 Genetics Inst Aus mehreren domänen bestehende hämatopoese- stimulatoren
US5372808A (en) † 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
DE69222013T2 (de) * 1991-12-16 1998-01-29 Ciba Geigy Ag Endoplasmatisches Retikulum-ständige rekombinante dibasische Endoprotease und deren Verwendungen
US5676942A (en) * 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
ATE175998T1 (de) * 1992-03-10 1999-02-15 Jolla Cancer Res Found Rekombinierte alkalische phosphatase aus kälberdarm
TW218846B (de) * 1992-04-07 1994-01-11 Ciba Geigy
JPH078215A (ja) * 1993-04-30 1995-01-13 Kawasaki Steel Corp ドコサヘキサエン酸含有海洋性微細藻類食品素材およびその製造方法
TW249202B (de) * 1993-08-13 1995-06-11 Ciba Gerigy Corp
US5981227A (en) 1995-02-09 1999-11-09 Movartis Ag Process for the production of proteins
TW442492B (en) * 1995-07-26 2001-06-23 Novartis Ag Process for the enrichment of interferon
US6685933B1 (en) 1998-07-28 2004-02-03 The United States Of America As Represented By The Department Of Health And Human Services Interferon α hybrids
EE05201B1 (et) 1998-10-16 2009-08-17 Biogen Idec Ma Inc. Glkoslitud interferoon-beeta, selle kasutamine ja seda sisaldav farmatseutiline kompositsioon, meetod interferoon-beeta-1a aktiivsuse pikendamiseks ja leiutisekohase valgu valmistamiseks
US6514729B1 (en) * 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
CA2427194A1 (en) * 2000-11-03 2002-05-10 Biomedicines, Inc. Method for short-term and long-term drug dosimetry
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
FR2821625B1 (fr) * 2001-03-01 2003-05-16 Genodyssee Nouveaux polynucleotides comportant un polymorphisme de type snp fonctionnel dans la sequence nucleotidique du gene ifn-alpha-2 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques
FR2823220B1 (fr) * 2001-04-04 2003-12-12 Genodyssee Nouveaux polynucleotides et polypeptides de l'erythropoietine (epo)
AU2002365436B8 (en) * 2001-11-09 2008-04-03 Intarcia Therapeutics, Inc. Method for treating diseases with omega interferon
US20040175359A1 (en) * 2002-11-12 2004-09-09 Desjarlais John Rudolph Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity
KR20050086498A (ko) * 2002-11-18 2005-08-30 맥시겐, 인크. 인터페론-알파 폴리펩티드 및 접합체
US7314613B2 (en) * 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
TW200611910A (en) * 2004-05-19 2006-04-16 Maxygen Inc Interferon-alpha polypeptides and conjugates
EP1771197A2 (de) * 2004-06-30 2007-04-11 Egen Corporation Pegyliertes interferon-alpha-1b
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
BRPI0609809A2 (pt) 2005-05-18 2011-10-11 Maxygen Inc polipeptìdeo isolado ou recombinante, conjugado, composição, polinucleotìdeo isolado ou recombinante, célula hospedeira, vetor, métodos para preparar o polipeptìdeo, para preparar um conjugado, para inibir replicação de um vìrus em células infectadas com o vìrus para reduzir o numero de cópias de um vìrus em células infectadas com o vìrus, para reduzir o nìvel de rna de hcv no soro de um paciente infectado com hcv, para reduzir o nìvel de dna de hbv em soro de um paciente infectado com hbv e para reduzir o nìvel de rna de hiv em soro de um paciente infectado com hiv, e, uso do polipeptìdeo ou do conjugado
MX2008014870A (es) 2006-05-30 2009-02-12 Intarcia Therapeutics Inc Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas.
EP2634250B1 (de) 2006-07-14 2017-04-05 Patheon Holdings I B.V. Verbessertes Verfahren zur Zellkultivierung
ES2422864T3 (es) 2006-08-09 2013-09-16 Intarcia Therapeutics, Inc Sistemas de liberación osmótica y unidades de pistón
US20100143372A1 (en) 2006-12-06 2010-06-10 Medimmune, Llc Interferon alpha-induced pharmacodynamic markers
AU2008244523B2 (en) 2007-04-23 2012-02-16 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
MX2009011870A (es) * 2007-05-02 2009-11-12 Ambrx Inc Polipeptidos de interferon beta modificados y usos de los mismos.
CA2686861A1 (en) 2007-05-03 2008-11-13 Medimmune, Llc Interferon alpha-induced pharmacodynamic markers
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
ES2557352T3 (es) 2007-11-05 2016-01-25 Medimmune, Llc Métodos de tratamiento de la esclerodermia
EP2848702A1 (de) 2008-02-08 2015-03-18 MedImmune, LLC Krankheitsmarker und Verwendungen davon
US8343140B2 (en) 2008-02-13 2013-01-01 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
AU2010289383B2 (en) 2009-09-03 2015-04-16 Medimmune, Llc Type 1 interferon diagnostic
EP3735944A1 (de) 2009-09-28 2020-11-11 Intarcia Therapeutics, Inc. Schnelle initiierung und/oder beendigung der verabreichung substantiell stabiler arzneimittel
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
SI2686002T1 (en) 2011-03-15 2018-06-29 Biogen Ma Inc. A method for reducing influenza-like symptoms associated with intramuscular delivery of interferon by the rapid titration-enhancing regimen
US8729236B2 (en) * 2011-05-23 2014-05-20 Hal S. Padgett Selection and characterization of novel plant-derived recombinant human interferons with broad spectrum activity
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
EP4278996A3 (de) 2015-06-03 2024-01-24 i2o Therapeutics, Inc. Systeme zum einsetzen eines implantats
AU2017268161B2 (en) 2016-05-16 2020-03-12 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
CA3049034A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
EA202192176A1 (ru) 2019-02-15 2022-01-13 Астразенека Аб Нарушения, опосредованные интерфероном i типа
KR102570958B1 (ko) * 2023-06-14 2023-08-25 (주) 신성하이스킬 화재방지 4축 파쇄장치
KR102594862B1 (ko) * 2023-06-14 2023-10-27 (주) 신성하이스킬 화재방지 파쇄 시스템

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CY1346A (en) * 1980-01-08 1987-01-16 Biogen Nv Dna sequences,recombinant dna molecules and processes for producing human interferon-like polypeptides
ES8302778A1 (es) * 1980-11-10 1983-02-01 Genentech Inc Un procedimiento para producir un polipeptido antiviral.
US4456748A (en) * 1981-02-23 1984-06-26 Genentech, Inc. Hybrid human leukocyte interferons
US4414150A (en) * 1980-11-10 1983-11-08 Genentech, Inc. Hybrid human leukocyte interferons
GB2108510B (en) * 1981-10-03 1984-12-12 Ciba Geigy Ag Dnas, recombinant dnas, hosts containing them, polypeptides and processes for the production thereof
IT1167610B (it) * 1982-01-19 1987-05-13 Cetus Corp Interfreron ibrido multiclasse, composizione farmaceutica che lo contiene e procedimento di produzione
GB8315980D0 (en) * 1983-06-10 1983-07-13 Biogen Nv Producing hybrid dna sequences
GB8317880D0 (en) * 1983-07-01 1983-08-03 Searle & Co Structure and synthesis of interferons
EP0146903A3 (de) * 1983-12-19 1987-07-22 Schering Corporation Herstellung eines ein Hybrid-Interferon-Spezies kodierenden Vektors
GB8412564D0 (en) * 1984-05-17 1984-06-20 Searle & Co Structure and properties
EP0173935A1 (de) * 1984-08-31 1986-03-12 University Patents, Inc. Hybrid-Lymphoblastoid-Leukozyten-Humaninterferone
US4716217A (en) * 1984-08-31 1987-12-29 University Patents, Inc. Hybrid lymphoblastoid-leukocyte human interferons

Also Published As

Publication number Publication date
NO175602B (no) 1994-07-25
PT82736B (pt) 1988-12-15
FI862461A (fi) 1986-12-12
EP0205404B1 (de) 1992-07-15
KR920002267B1 (ko) 1992-03-20
IL79085A (en) 1992-03-29
KR870000427A (ko) 1987-02-18
DK272986D0 (da) 1986-06-10
PT82736A (en) 1986-07-01
FI90983B (fi) 1994-01-14
DK168794B1 (da) 1994-06-13
JPS626000A (ja) 1987-01-12
AU598196B2 (en) 1990-06-21
CA1285507C (en) 1991-07-02
FI862461A0 (fi) 1986-06-09
IE57865B1 (en) 1993-05-05
EP0205404A2 (de) 1986-12-17
US5071761A (en) 1991-12-10
JPH05308973A (ja) 1993-11-22
IL79085A0 (en) 1986-09-30
CY1842A (en) 1996-03-08
GR861497B (en) 1986-10-10
HU203255B (en) 1991-06-28
HUT41846A (en) 1987-05-28
NO862313D0 (no) 1986-06-10
DE3685996T2 (de) 1993-01-14
DE3685996D1 (de) 1992-08-20
JPH0736757B2 (ja) 1995-04-26
AU5849986A (en) 1986-12-18
JPH0655759B2 (ja) 1994-07-27
IE861542L (en) 1986-12-11
HK99895A (en) 1995-06-30
US4885166A (en) 1989-12-05
DK272986A (da) 1986-12-12
NZ216485A (en) 1991-06-25
EP0205404A3 (en) 1987-10-21
NO175602C (no) 1994-11-02
NO862313L (no) 1986-12-12
FI90983C (fi) 1994-04-25
SG25195G (en) 1995-08-18

Similar Documents

Publication Publication Date Title
ATE78262T1 (de) Hybrid-interferone.
DE3583521D1 (de) Antivirale verbindungen.
IT8124967A0 (it) Interferoni di leucociti umani ibridi.
FI863378A0 (fi) Rengoeringsfoerfarande av interferon.
FI850275L (fi) Nya 6-susbtituerade furo-(3,4-c) -pyridinderivat.
FR2431507A1 (fr) 1-desamino-2-desoxy-2-epi-amino fortimicine b
FI872096A0 (fi) Foerhoejd expression av humant interleukin-2 i daeggdjursceller.
EP0315637A4 (de) Polypeptide zur verwendung bei der diagnose von mycoplasmainfektionen bei schweinen, sowie rekombinant-dns-verfahren zur herstellung derselben.
NO873389D0 (no) Homogent rekombinant immun-interferon-fragment.
DE3577713D1 (de) Thermoplastische, weichmacherhaltige polyvinylbutyralformmassen.
DE3575435D1 (de) Sinterfaehige, feinteilige formmasse auf basis von vinylchlorid-polymerisaten.
NO861635L (no) Fremgangsmaate for fremstilling av rekombinert aaa-interferon.
NO894573L (no) Rekombinante interleukin-2 hybridproteiner.
ES8600321A1 (es) Un procedimiento para obtener compuestos de ribofuranosilselenazol-4-carboxamida-5'-fosfato
FI841787A (fi) Nya vektorer foer expression av interferon.
ATA551881A (de) Dreilagiger formkoerper, insbesondere blech, von hoher verschleissfestigkeit
SU939352A1 (ru) Двухмассный вибрационный конвейер
ES2052562T3 (es) Peptido antineoplasico inducido por la interleucina-2.
DE3783697D1 (de) Antitumor-verbindungen.
DE3673139D1 (de) Sinterfaehige, feinteilige formmasse auf basis von vinylchlorid-polymerisaten.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time